Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round
The funding will advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and neurologic conditions.New investors include Dementia Discovery Fund, Leaps by Bayer, and UPMC Enterprises.CARMEL, Ind.--(BUSINESS WIRE)--#TYK2--Sudo Biosciences (“Sudo”), a biophar...
Source: pharmiweb.com